CGEM241220P30000
- 0.00
- 0.000.00%
Cullinan Therapeutics Newsroom
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook
We're Not Very Worried About Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $34
Leerink Partners Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28
Express News | Cullinan Therapeutics Inc : Jonestrading Raises Target Price to $34 From $29
Cullinan Therapeutics: Promising Developments and Strategic Growth in Autoimmune Therapies
Morgan Stanley Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $38
TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating
Cullinan Therapeutics | 10-Q: Q3 2024 Earnings Report
Cullinan Therapeutics 3Q Loss $40.6M >CGEM
Cullinan Therapeutics | 8-K: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Cullinan Therapeutics Reports Q3 EPS (69c), Consensus (81c)
Cullinan Therapeutics Sees Cash Runway Into 2028
Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Express News | Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Express News | Cullinan Oncology Q3 Cash & Investments USD 639 Million
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
Cullinan Therapeutics to Present Preclinical Data for CLN-978
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus